# SGLT2 Inhibitors Clinical Uses

> SGLT2 inhibitors clinical uses for NEET-PG Medicine, covering cardiorenal benefits in diabetes, heart failure and CKD, plus infection and ketoacidosis risks.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/sglt2-inhibitors-clinical-uses
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: Harrison's Principles of Internal Medicine; Davidson's Principles and Practice of Medicine; Goodman and Gilman's The Pharmacological Basis of Therapeutics
- How to cite: "SGLT2 Inhibitors Clinical Uses", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/sglt2-inhibitors-clinical-uses

## Direct answer

SGLT2 inhibitors such as empagliflozin, dapagliflozin and canagliflozin block glucose and sodium reabsorption in the proximal tubule, lowering blood glucose and giving cardiorenal protection that does not depend on glycaemic control. They are used in type 2 diabetes, heart failure and chronic kidney disease. Their main hazards are genital mycotic infection, volume depletion and euglycaemic ketoacidosis.

## What you must remember

- **Mechanism:** inhibition of SGLT2 in the proximal convoluted tubule causes glycosuria and mild natriuresis, and the glucose-lowering effect weakens as eGFR falls.
- **Diabetes:** modest HbA1c reduction with low hypoglycaemia risk when used alone, and useful weight loss.
- **Heart failure:** dapagliflozin and empagliflozin reduce hospitalisation for heart failure across both reduced and preserved ejection fraction.
- **Chronic kidney disease:** slower progression of kidney disease, including proteinuric disease, with or without diabetes.
- **Genital infection:** genital mycotic infection and urinary tract infection are common, and Fournier's gangrene is a rare but serious risk.
- **Ketoacidosis:** euglycaemic diabetic ketoacidosis can occur with near-normal glucose, especially during fasting, surgery or acute illness.
- **Volume depletion:** natriuresis causes dehydration and hypotension, particularly alongside loop diuretics.

## A stepwise approach to starting therapy

A 62-year-old man with type 2 diabetes, heart failure with reduced ejection fraction and an eGFR of 40 is being considered for an SGLT2 inhibitor. The decision rests on the indication and on safety checks rather than on the blood glucose alone.

1. **Confirm the indication:** type 2 diabetes with cardiovascular or renal risk, heart failure across the ejection fraction range, or chronic kidney disease, each of which is a reason in its own right.
2. **Check renal function:** confirm the eGFR, since glucose-lowering weakens as kidney function falls while the cardiorenal benefit persists at lower levels.
3. **Assess volume and drugs:** check for dehydration, low blood pressure and concurrent diuretics, and reduce the loop diuretic if volume depletion is likely.
4. **Counsel on infection and ketosis:** explain genital hygiene and sick-day rules, and teach the symptoms of ketoacidosis such as nausea, vomiting and breathlessness with normal glucose.
5. **Hold before surgery:** stop the drug about three days before elective surgery and during acute illness or prolonged fasting, restarting once eating normally.
6. **Monitor and continue:** review kidney function, volume status and genital symptoms at follow-up, and continue long term while the benefit is established.

## High-yield viva angles

Viva questions test whether the reason for prescribing and the risks are understood together.

- **Trap:** assuming glucose-lowering is the main reason to prescribe in heart failure or kidney disease — **Correct:** the cardiorenal benefit is the reason, and it is seen in patients without diabetes too.
- **Trap:** dismissing ketoacidosis because glucose is near normal — **Correct:** euglycaemic ketoacidosis presents with near-normal glucose, so ketones are checked in nausea, vomiting or breathlessness.
- **Trap:** continuing the drug through a planned major operation — **Correct:** stopping about three days beforehand lowers the risk of ketoacidosis during fasting.

## Frequently asked questions

### Why are SGLT2 inhibitors used in heart failure in patients without diabetes?

SGLT2 inhibitors such as dapagliflozin and empagliflozin reduce hospitalisation for heart failure in patients with and without diabetes. The heart failure benefit does not depend on lowering blood glucose. These drugs are therefore indicated across the ejection fraction range.

### What is euglycaemic diabetic ketoacidosis with SGLT2 inhibitors?

Euglycaemic diabetic ketoacidosis is ketoacidosis with blood glucose below the usual threshold for diabetic ketoacidosis, and it can occur with SGLT2 inhibitors. It is more likely during fasting, surgery, prolonged vomiting or acute illness. Patients should be taught to recognise nausea, vomiting and breathlessness and seek urgent review.

### Why do SGLT2 inhibitors cause genital infections?

SGLT2 inhibitors cause glycosuria, which creates a glucose-rich urine that favours yeast and bacterial growth in the genital tract. Genital mycotic infection and urinary tract infection are the common effects. Fournier's gangrene is a rare but serious necrotising infection that patients should be taught to recognise early.

### When should an SGLT2 inhibitor be stopped before surgery?

An SGLT2 inhibitor is typically stopped about three days before elective surgery, because fasting raises the risk of euglycaemic ketoacidosis. It is restarted once the patient is eating and drinking normally and kidney function is stable. The timing is confirmed against the local anaesthesia and surgical protocol.